Aiming Yu, Ph.D. Professor
Director of The PK/PD Bioanalytical Core Facility
Oak Park Research Building
Room 2132
2700 Stockton Blvd.
Sacramento, CA 96817
Ph: 916-734-1566
Fax: 916-734-4418

Dr. Yu’s research interests include noncoding microRNA pharmacoepigenetics and cancer therapy. The ultimate goal of his research is to translate noncoding RNAs to new therapeutics. Current efforts in his laboratory are directed to the investigation of (a) the mechanistic actions of microRNAs in the regulation of cancer cellular processes including drug disposition and tumor progression, and (b) novel genetically engineered noncoding RNAs as cancer therapeutics.

Dr. Yu also directs The PK/PD Bioanalytical Core Facility at UC Davis that is set up to provide bioanalytical services in support of the clinical and preclinical drug development programs. Investigators who are in need of the services may directly contact the Core Facility Manager Dr. Jimmy Wu

Zhang K, Bian J, Deng Y, Smith A, Nunez RE, Li MB, Pal U, Yu AM, Qiu W, Ealick SE, and Li CH. Lyme disease spirochete Borrelia burgdorferi does not require thiamin. Nature Microbiol. Nov. 21, 2:16213 (2016).

Jiang XL, Shen HW, Mager DE, Schmidt S, Yu AM. Development of a Mechanism-Based Pharmacokinetic/Pharmacodynamic Model to Characterize the Thermoregulatory Effects of Serotonergic Drugs in Mice. Acta Pharm Sin B. 6(5):492-503 (2016).

Tu MJ, Pan YZ, Qiu JX, Kim E, Yu AM. MicroRNA-1291 targets the FOXA2-AGR2 pathway to suppress pancreatic cancer cell proliferation and tumorigenesis. Oncotarget. 7(29):45547-45561 (2016).

Zhao Y, Tu MJ, Wang WP, Qiu JX, Yu AX, Yu AM. Genetically engineered miR-34a prodrug suppresses orthotopic osteosarcoma tumor growth via the induction of apoptosis and cell cycle arrest. Sci Rep. 6:26611 (2016).

Wang WP, Ho PY, Li MM, Chen QX, Addepalli B, Tu MJ, Limbach PA, Li MM, Wu WJ, Jilek JL, Qiu JX, Zhang HJ, Li T, Wun T, DeVere White R, Lam KS, Yu AM. Bioengineering novel chimeric microRNA-34a for prodrug cancer therapy: High-yield expression and purification, and structural and functional characterization. J. Pharmacol. Exp. Ther. 354(2):131-141 (2015).

Li MM, Addepalli B, Tu MJ, Chen QX, Wang WP, Limbach PA, LaSalle JM, Zeng S, Huang M, Yu AM. Chimeric miR-1291 biosynthesized efficiently in E. coli is effective to reduce target gene expression in human carcinoma cells and improve chemosensitivity. Drug Metab Dispos. 43(7):1129-1136 (2015).

Chen QX, Wang WP, Zeng S, Uroyama S, Yu AM. A general approach to high-yield biosynthesis of chimeric RNAs bearing various types of functional small RNAs for broad applications. Nucleic Acids Res, 43(7):3857-3869 (2015).

Jiang XL, Shen HW, and Yu AM. Potentiation of 5-methoxy-N,N-dimethyltryptamine-induced hyperthermia by harmaline and the involvement of activation of 5-HT1A and 5-HT2A receptors. Neuropharmacology, 89:342-351 (2015).

Li MM, Wang WP, Wu WJ, Huang M, and Yu AM. Rapid production of novel pre-microRNA agent hsa-mir-27b in Escherichia coli using recombinant RNA technology for functional studies in mammalian cells. Drug Metab Dispos. 42(11):1791-1795 (2014).

Bi HC, Pan YZ, Qiu JX, Krausz KW, Li F, Johnson CH, Jiang CT, Gonzalez FJ, and Yu AM. N-methylnicotinamide and nicotinamide N-methyltransferase are associated with microRNA-1291 altered pancreatic carcinoma cell metabolome and suppressed tumorigenesis. Carcinogenesis, 35(10):2264-2272 (2014).

Pan YZ, Zhou A, Hu Z, Yu AM. Small nucleolar RNA-derived microRNA hsa-miR-1291 modulates cellular drug disposition through direct targeting of ABC transporter ABCC1. Drug Metab Dispos. 41(10):1744-1751 (2013).

Jiang XL, Shen HW, Mager DE, Yu AM. Pharmacokinetic interactions between monoamine oxidase A inhibitor harmaline and 5-methoxy-N,N-dimethyltryptamine, and the impact of CYP2D6 status, Drug Metab Dispos. 41(5):975-986 (2013).

See other publications on PubMed.

Graduate Courses

  • PTX201 Principles of Pharmacology and Toxicology I
  • VMB253 Drug Metabolism and Disposition
  • BCB299 Research
  • PTX299 Research